Abstract
Glycogen synthase kinase (GSK) was initially described as a key enzyme involved in glycogen metabolism. However, since that time it has been found to regulate a diverse range of cell functions. In addition to having a major role in the regulation of the important onco-protein β-catenin, GSK is also a critical regulator of NF-κB. NF-κB comprises a family of transcription factors which activate the expression of a wide array of genes involved in inflammation, tumourigenesis, metastasis, differentiation, embryonic development, apoptosis . Inflammation mediated by the NF-κB family has been implicated in the initiation of pancreatic cancer, resistance to chemotherapy and the development of the debilitating cancer cachexia seen with advanced disease. Hence, GSK has potential as an important new target both in the treatment of resectable pancreatic cancer as an adjuvant to surgery, and in the palliation of inoperable tumours.
Keywords: Inflammation, pancreatic cancer, glycogen synthase kinase
Current Cancer Drug Targets
Title: Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Volume: 7 Issue: 3
Author(s): G. Garcea, M. M. Manson, C. P. Neal, C. J. Pattenden, C. D. Sutton, A. R. Dennison and D. P. Berry
Affiliation:
Keywords: Inflammation, pancreatic cancer, glycogen synthase kinase
Abstract: Glycogen synthase kinase (GSK) was initially described as a key enzyme involved in glycogen metabolism. However, since that time it has been found to regulate a diverse range of cell functions. In addition to having a major role in the regulation of the important onco-protein β-catenin, GSK is also a critical regulator of NF-κB. NF-κB comprises a family of transcription factors which activate the expression of a wide array of genes involved in inflammation, tumourigenesis, metastasis, differentiation, embryonic development, apoptosis . Inflammation mediated by the NF-κB family has been implicated in the initiation of pancreatic cancer, resistance to chemotherapy and the development of the debilitating cancer cachexia seen with advanced disease. Hence, GSK has potential as an important new target both in the treatment of resectable pancreatic cancer as an adjuvant to surgery, and in the palliation of inoperable tumours.
Export Options
About this article
Cite this article as:
Garcea G., Manson M. M., Neal P. C., Pattenden J. C., Sutton D. C., Dennison R. A. and Berry P. D., Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?, Current Cancer Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/156800907780618266
DOI https://dx.doi.org/10.2174/156800907780618266 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Insights in microRNAs Biology
Current Topics in Medicinal Chemistry Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Tumour Reactions to Hypoxia
Current Molecular Medicine The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery